Skip to content

Climb Bio, Inc. (CLYM) Insider Trading -- Recent Executive & Director Transactions

10 insiders reported 69 Form 4 transactions for Climb Bio, Inc. (CLYM) over the past 18 months (most recent 2026-09-30). Recent activity: RA Capital Healthcare Fund LP (Director) Buy 10,000 shares, RA Capital Nexus Fund II, L.P. (Director) Buy 10,000 shares, Kolchinsky Peter (Director) Buy 10,000 shares, Shah Rajeev M. (Director) Buy 10,000 shares, RA Capital Nexus Fund, L.P. (Director) Buy 10,000 shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-09-30RA Capital Healthcare Fund LPDirectorBuy10,000$34,600
2026-09-30RA Capital Nexus Fund II, L.P.DirectorBuy10,000$78,900
2026-09-30Kolchinsky PeterDirectorBuy10,000$34,600
2026-09-30Shah Rajeev M.DirectorBuy10,000$34,600
2026-09-30RA Capital Nexus Fund, L.P.DirectorBuy10,000$34,600
2026-09-30RA Capital Nexus Fund II, L.P.DirectorBuy10,000$34,600
2026-09-30RA Capital Nexus Fund III, L.P.DirectorBuy10,000$34,600
2026-09-30RA CAPITAL MANAGEMENT, L.P.DirectorBuy10,000$34,600
2026-09-30RA CAPITAL MANAGEMENT, L.P.DirectorBuy10,000$30,000
2026-09-30Kolchinsky PeterDirectorBuy10,000$30,000
2026-09-30Shah Rajeev M.DirectorBuy10,000$30,000
2026-09-30RA Capital Nexus Fund, L.P.DirectorBuy10,000$30,000
2026-09-30RA Capital Nexus Fund II, L.P.DirectorBuy10,000$30,000
2026-09-30RA Capital Nexus Fund III, L.P.DirectorBuy10,000$30,000
2026-09-30RA Capital Healthcare Fund LPDirectorBuy10,000$78,900
2026-09-30RA CAPITAL MANAGEMENT, L.P.DirectorBuy10,000$78,900
2026-09-30Kolchinsky PeterDirectorBuy10,000$78,900
2026-09-30Shah Rajeev M.DirectorBuy10,000$78,900
2026-09-30RA Capital Nexus Fund, L.P.DirectorBuy10,000$78,900
2026-09-30Shah Rajeev M.DirectorBuy40,000$51,600
2026-09-30RA Capital Nexus Fund III, L.P.DirectorBuy10,000$78,900
2026-09-30RA Capital Healthcare Fund LPDirectorBuy40,000$51,600
2026-09-30RA CAPITAL MANAGEMENT, L.P.DirectorBuy40,000$51,600
2026-09-30Kolchinsky PeterDirectorBuy40,000$51,600
2026-09-30RA Capital Healthcare Fund LPDirectorBuy10,000$30,000

Source: SEC Form 4 filings · as of 2026-09-30